Barclays Reaffirms Their Hold Rating on Smith & Nephew (SN)
Barclays analyst Hassan Al-Wakeel maintained a Hold rating on Smith & Nephew today and set a price target of £13.05.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Al-Wakeel covers the Healthcare sector, focusing on stocks such as Straumann Holding AG, EssilorLuxottica SA, and Koninklijke Philips N.V.. According to TipRanks, Al-Wakeel has an average return of 0.1% and a 47.93% success rate on recommended stocks.
In addition to Barclays, Smith & Nephew also received a Hold from RBC Capital’s Jack Reynolds-Clark in a report issued on February 26. However, yesterday, Morgan Stanley maintained a Buy rating on Smith & Nephew (LSE: SN).
Based on Smith & Nephew’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of p2.99 billion and a net profit of p295.65 million. In comparison, last year the company earned a revenue of p2.83 billion and had a net profit of p214 million
Read More on GB:SN:
Disclaimer & DisclosureReport an Issue
- Smith & Nephew: Resilient Fundamentals and Earnings Momentum Support Buy Rating
- Smith & Nephew announces U.S. distribution agreement with RMR Ortho
- Smith & Nephew signs distribution agreement with SI-Bone
- Smith & Nephew: Underappreciated Sports Medicine Growth Platforms Support Re‑Rating Potential and Justify Buy Rating
- Smith & Nephew: Strategic Integrity Orthopaedics Acquisition and Underappreciated Sports Medicine Growth Support Buy Rating
